Russ, this is my point being the cash burn which is unsustainable and IMO the wrong strategy. AHZ should either partner now with big pharma at Phase 1 to de-risk the vax or alternatively fund Phase 2 from strong free cash flows which could be in the next few years possibly CY2017.
Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-72
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.50 |
Change
-0.500(3.33%) |
Mkt cap ! $311.5M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.00 | $14.50 | $31.93K | 2.171K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 60 | $14.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.66 | 275 | 1 |
View Market Depth
| Last trade - 10.59am 15/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |